Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom

Becton Dickinson is positioned to benefit from the GLP-1 boom, with management announcing a $110M expansion to increase prefillable syringe capacity as demand rises through the end of the decade. Abbott Laboratories’ FreeStyle Libre CGM demand is holding up and potentially rising alongside GLP-1 prescriptions, supported by evidence of higher sensor adherence among patients on GLP-1s. Both companies are highlighted as Dividend Kings with 54 consecutive years of dividend increases, supporting an income-oriented long-term thesis.

Analysis

The investable takeaway is not that GLP-1s themselves are the trade, but that the adoption curve is leaking into a broader “ecosystem tax” on medtech inputs and monitoring. BDX is the cleaner pure-play on procedure volume and consumables, but the market should discount much of the announced expansion until it shows up in utilization and mix; prefillable syringes are a volume story, not a high-margin moat story, so upside is likely steady rather than explosive.

ABT has the more interesting second-order setup: if GLP-1 therapy improves adherence and keeps patients engaged with physicians, CGM can become complementary infrastructure rather than a displaced category. That supports recurring revenue durability over 2-4 quarters and a better multiple than the market is likely assigning after the recent underperformance. The main falsifier is any evidence that better glycemic control reduces sensor days faster than GLP-1 attach expands.

Contrarian view: consensus is chasing the obvious winners and may be underweighting the “support layer” beneficiaries, but BDX’s capacity spend could also be a tell that the easy money has already been competed away. If syringe demand does not convert into visible margin expansion by the next two earnings cycles, this becomes a low-beta income stock, not an alpha generator. In contrast, ABT looks more mispriced because the market is still debating substitution risk that the usage data may already be disproving.

Key Decisions for Investors

• Long ABT on 3-5% pullbacks; 6-12 month horizon, with upside if CGM growth reaccelerates and the market awards a higher quality-growth multiple. Falsify if Libre growth slows to low-single digits for two consecutive quarters.
• Tactical long BDX only as a smaller position or starter stake ahead of the next print; 1-3 month catalyst window. Require evidence of order conversion/backlog flow-through before adding, because capex announcements alone do not guarantee EPS upside.
• Pair trade: long BDX / short IHI for 2-4 months to isolate GLP-1-linked medtech demand from the broader device basket. Exit if BDX margin commentary disappoints or the ETF outperforms on unrelated hospital/procedure strength.
• Keep LLY and NVO as core GLP-1 exposure, but fund any incremental healthcare allocation with ABT rather than adding more direct drug beta; the cleaner risk/reward is in ecosystem capture, not category leadership.
• Set a watch item for payer policy or oral GLP-1 adoption; either could reduce device attach. If that shows up in utilization data, cut the ABT/BDX thesis quickly.